RTEL1 and central nervous system cancer: To further examine the relationship of the RTL and the expression of RTEL1 with clinicopathological characteristics of glioma patients, we calculated 95% CI (0.15–0.62) of RTL, (0.87–3.98) of RTEL1 mRNA in non-glioma control tissue, then define 0.62 and 3.98 as cut-off values of RTL and RTEL1 mRNA, respectively.